Abstract
We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Child, Preschool
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Male
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Rituximab
-
Salvage Therapy / methods*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Rituximab